原位杂交与免疫组化技术用于评价化疗后结直肠癌患者MLH1、MSH2和hMSH6表达水平的对比研究

目的 探讨原位杂交方法和免疫组化方法两种不同方法在检测评价直肠癌术后新辅助化疗治疗后患者三种错配修复蛋白(hMLH1、hMSH2和hMSH6)表达水平的效果。方法选取本院收治的散发性结直肠癌(SCRC)患者260例,取手术切除的肿瘤组织,使用较原位杂交和免疫组化法测定hMLH1、hMSH2和hMSH6表达水平的效果,比较三种指标之间的关联性。结果不同部位的肿瘤各种特征之间未见明显差别。原位杂交法检测hMLH1、hMSH2、hMSH6的阳性率显著高于免疫组化检测的阳性率；免疫组化法检测结果提示hMLH1与hMSH2的表达无明显相关性,hMLH1或hMSH2与hMSH6表达分别呈正相关;原位杂交法检测结果提示hMLH1与hMSH2,hMLH1与hMSH6,hMSH2与hMSH6表达均呈正相关。结论原位杂交法和免疫组化方法两种方法在检测评价直肠癌术后辅助化疗后患者三种错配修复蛋白hMLH1、hMSH2和hMSH6表达水平的效果中原位杂交法更优。

A comparison of in situ hybridization and immunohistochemistry in evaluating the expression of MLH1,MSH2 and hMSH6 in colorectal cancer patients after chemotherapy

Objective To evaluate the expression of three mismatch repair proteins (hMLH1,hMSH2 and hMSH6) in neoadjuvant chemotherapy patients after rectal cancer resection by two different methods of in situ hybridization and immunohistochemistry.Methods260 patients suffered from sporadic colorectal carcinoma(SCRC) admitted to our hospital were studied.The expression of hMLH1,hMSH2 and hMSH6 were detected by in situ hybridization and immunohistochemistry,the correlation of hMLH1,hMSH2 and hMSH6 was compared.ResultsThere was no significant difference in the tumor characteristics of different parts.The rate of positive expression of hMLH1,hMSH2 and hMSH6 detected by in situ hybridization was significantly higher than that of immunohistochemistry,respectively (P<0.01).The immunohistochemistry result showed that there was no correlation between hMLH1 and hMSH2 expression,but hMLH1 or hMSH2 was positively correlated with hMSH6 expression,respectively.The expressions of hMLH1,HMSH2 and hMSH6 detected by in situ hybridization were positively correlated among the SCRC tumor tissues.ConclusionIn situ hybridization and immunohistochemistry are two best methods to evaluate the expression of three mismatch repair proteins hMLH1,hMSH2 and hMSH6 in postoperative neoadjuvant chemotherapy patients after rectal cancer.